Viz.ai Funding Will Support Expansion of AI-Driven Viz Platform for Disease Detection and Triage

April 7, 2022—Viz.ai announced it has completed a $100 million Series D funding round led by Tiger Global and Insight Partners. The funding raises the company’s valuation to $1.2 billion. Also joining the round were several of the company’s early backers including Scale Ventures, Kleiner Perkins, Threshold, GV (formerly Google Ventures), Sozo Ventures, CRV, and Susa.

The company stated that the new funds will be used to support the company’s growth including the expansion of the Viz platform to detect and triage additional diseases.

According to Viz.ai, its artificial intelligence (AI) technology connects radiologists, emergency physicians, and primary care practitioners to the optimal specialists for a particular disease to facilitate care coordination and ensure optimized and consistent care pathways, reducing variability. It combines actionable computational diagnostics and precision medicine to improve patient outcomes and the financial efficiency of a health system.

The funding announcement follows the launch of Viz.ai’s AI-driven life science platform for medical device and pharmaceutical companies to perform clinical trials and bring their treatments to market.

In the past year, Viz.ai launched solutions for aortic disease, pulmonary embolism, cerebral aneurysms, and is 510(k) pending for subdural hematoma. Additionally, the company was granted its first five CE Mark approvals in 2021.

In the stroke detection and triage market, Viz.ai's stroke module has received FDA de novo clearance and its AI software received approval for a New Technology Add-on Payment from the Centers for Medicare & Medicaid Services.

Chris Kellner, MD, a cerebrovascular neurosurgeon in the Mount Sinai Health System in New York, New York, commented in the company’s press release, “The Viz.ai platform has been the single most impactful advance I’ve seen as a physician, permitting the entire care team to mobilize immediately and deliver time sensitive treatment faster. In addition, Viz Recruit permits us to automatically screen patients for clinical trial enrollment, ensuring we can offer cutting edge studies and treatments to more eligible patients.”

John Curtius, Partner at Tiger Global, added, “Viz.ai is the stand-out AI health care company; they are first-in-class in intelligent care coordination, with a solid foundation of clinical evidence supporting the value delivered to healthcare providers and patients. We see meaningful upside as the company expands to help life science companies expedite clinical trials and accelerate patient access to new effective treatments.”

Finally, Chris Mansi, MD, Viz.ai Cofounder and CEO, stated, “Viz.ai is committed to helping patients get better, faster, and more equitable access to life saving treatments. We will continue to invest heavily in cutting edge technology and services to integrate deeply into the clinical workflow, allowing us to automate disease detection, increase diagnostic rates, and enhance workflows across the entire hub and spoke health system. More patients receive the right treatment, resulting in better patient outcomes and improved financial efficiency for the health system.”